ethyl (S)-2-bromo-valerate | 885478-43-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl (S)-2-bromo-valerate
• 英文别名: ethyl (2S)-2-bromopentanoate
• CAS: 885478-43-3
• 化学式: C₇H₁₃BrO₂
• 分子量: 209.083
• InChiKey: ORSIRXYHFPHWTN-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴戊酸乙酯 在 column coated with 6-TBDMS-2,3-di-O-methyl-β-CD 作用下， 生成 ethyl (R)-2-bromo-valerate 、 ethyl (S)-2-bromo-valerate
  参考文献：
  名称：

  GC分离6-TBDMS-2,3-二烷基-β-和γ-环糊精固定相上的2-溴取代的羧酸对映体的烷基酯对映体

  摘要：

  在4种不同的6-TBDMS-2,3-di-O-烷基-β-和γ-CD固定相上研究了2-Br羧酸衍生物对映体的气相色谱分离。热力学数据的差异{ ΔH和–ΔS}对15个与结构相关的外消旋体进行了评估。详细研究了共价连接到立体碳原子上的烷基取代基以及同源分析物的酯基中结构差异的影响，以及改性β-和γ-环糊精衍生物的选择性。环糊精空腔的大小，以及6-TBDMS-β-CD的2和3位的烷基取代基的延伸，也影响了它们的选择性。对映体分离的质量主要受分子酯基团的烷基链影响，这似乎与所用的CD固定相无关。在某些情况下，分离是由于外部吸附而不是与手性选择剂形成包合物而发生的。手性26：279–285，2014。©2014 Wiley Periodicals，Inc.

  DOI：

  10.1002/chir.22310

文献信息

• 5-Substituted 1,1-dioxo-'1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
  申请人：Coppola Mark Gary

  公开号：US20050090502A1

  公开（公告）日：2005-04-28

  Compounds of the formula provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式I的化合物提供了药理剂，这些药理剂是PTP酶的抑制剂，特别是公式I的化合物可以抑制PTP-1B和TC PTP，因此可用于治疗与PTP酶活性相关的疾病。本发明的化合物还可用于抑制具有磷酸酪氨酸结合区域的其他酶，例如SH2结构域。因此，公式I的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病相关的胰岛素抵抗症状。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的多种疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢紊乱以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• Cyclic sulfamide derivatives and methods of use
  申请人：——

  公开号：US20040023974A1

  公开（公告）日：2004-02-05

  Compounds of the formula 1 provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式1的化合物可提供药理学制剂，这些制剂是PTP酶的抑制剂，特别是公式I的化合物抑制PTP-1B和TC PTP，因此可用于治疗与PTP酶活性相关的疾病。本发明的化合物也可用于抑制其他具有磷酸酪氨酸结合区域（如SH2结构域）的酶。因此，公式I的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的许多疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives
  申请人：Coppola Gary Mark

  公开号：US20080139576A1

  公开（公告）日：2008-06-12

  Compounds of the formula provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  化合物的公式提供了药理剂，这些药理剂是PTP酶的抑制剂，特别是公式I的化合物抑制PTP-1B和TC PTP，因此可用于治疗与PTP酶活性相关的疾病。本发明的化合物也可用于抑制其他具有磷酸酪氨酸结合区域（如SH2结构域）的酶。因此，公式I的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗症状。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的许多疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症、失调脂质代谢和其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
  申请人：Murata Masakazu

  公开号：US20100286210A1

  公开（公告）日：2010-11-11

  An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like. The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I): (In the formula (I), the ring A represents phenyl group or the like; X represents —O— or the like; Y represents ═N— or the like; a and b represent methylene group or the like; both V and Z represent —O— or the like; W represents a C 1 -C 10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C 1 -C 6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R 1 represents methyl group or the like; R 2 represents methoxy group or the like; and R 3 represents carboxy group or the like.)

  本发明的目的是提供新型的咔唑衍生物、其溶剂化物或药学上可接受的盐，具有优异的减轻脂肪组织重量、降血糖和降血脂作用，可用作预防和/或治疗脂肪肝、肥胖症、脂质代谢异常、内脏脂肪、糖尿病、高脂血症、糖耐量受损、高血压、非酒精性脂肪肝病、非酒精性脂肪性肝炎等的药物。上述目的可以通过咔唑衍生物、其溶剂化物或药学上可接受的盐来实现，其中咔唑衍生物由下式(I)表示：（在式(I)中，环A表示苯基或类似物；X表示-O-或类似物；Y表示═N-或类似物；a和b表示甲基烷基或类似物；V和Z都表示-O-或类似物；W表示C1-C10烷基，其1或2个氢原子可被苯基或C1-C6烷基取代；1,2-苯基烷基；1,3-环己基烷基或类似物；R1表示甲基或类似物；R2表示甲氧基或类似物；R3表示羧基或类似物。）
• 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors
  申请人：Novartis AG

  公开号：EP2341049A1

  公开（公告）日：2011-07-06

  Compounds of the formula wherein L1, L2, L3, Q1, Q2, R1, R2, X, Y and Z are as decribed in the description fo the invention, provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  式中的化合物 其中 L1、L2、L3、Q1、Q2、R1、R2、X、Y 和 Z 如本发明所述，提供了作为 PTP 酶抑制剂的药剂，特别是式 I 化合物抑制 PTP-1B 和 TC PTP，因此可用于治疗与 PTP 酶活性相关的疾病。因此，式 I 化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大血管及小血管缺血性疾病相关的胰岛素抵抗。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性疾病和传染性疾病，以及涉及炎症和免疫系统的疾病。